Clinical trials: Body Mass Index
Obesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with obesity.
- Trial name
- NCT07142707
- Testing
- MBX 4291
- Where
- 4 sites in United States
- Volunteers
- 124 people
- Sponsor
- MBX Biosciences
Body Weight Changes
Efficacy Of Trimrox On Body Recomposition And Weight Management (TRCAP21)
Protocol Number: VNI/121/TrimRox: A unique stimulant- and sugar-free TRCAP21 Prodosomed® nutraceutical formulation, TrimROXTM, has been developed in a cGMP and NSF-certified manufacturing facility that is CFR-111 A compliant as…
- Trial name
- VNI (NCT05283525)
- Testing
- Anthropometric Measurement of the Chest, Upper Arm/Bicep, Hips, Thighs and Waist/ Belly in Inches, Oxygen Saturation, Total Blood Chemistry
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Victory Nutrition International, Inc.
Obesity
Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066
The purpose of this study was to determine if LIK066 taken with a meal containing low carbohydrate is associated with less diarrhea compared to a high carbohydrate meal and to assess the potential effects of supplements such as…
- Trial name
- NCT03198767
- Testing
- LIK066, Carbohydrate 50%, Carbohydrate 25%
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Obesity, Diabetes Mellitus, Type 2
A Study of the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Patients With Type 2 Diabetes
The purpose of this study is to investigate (1) the effect of topiramate on insulin sensitivity in overweight or obese patients with type 2 diabetes mellitus and (2) the safety of topiramate in type 2 diabetic patients.
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00236626
- Testing
- topiramate
- Volunteers
- 38 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity
Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years
This study will be conducted to demonstrate weight loss efficacy by change in body mass index (BMI) and safety in adolescents age 12 to 17 years (inclusive) during 52 weeks of treatment with Belviq XR 20 milligrams (mg)…
- Trial name
- NCT03338296
- Testing
- lorcaserin hydrochloride XR
- Where
- 16 sites in United States
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Non-alcoholic Steatohepatitis
First-in-Human Study of GM-60106 in Healthy Adults and Otherwise Healthy Adults With an Increased Body Mass Index and Markers of Non-Alcoholic Fatty Liver Disease
This is a Phase 1a/1b, randomised, double-blind, placebo-controlled single- and multiple-ascending dose study to evaluate the safety, tolerability, PK, and PD of GM-60106 in healthy adult male and female participants and…
- Trial name
- NCT05517564
- Testing
- GM-60106
- Where
- 2 sites in Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- JD Bioscience Inc.
Obesity, Overweight
A Post-approval LAP-BAND® Lower Body Mass Index (LBMI) Study
This is a post-approval, multicenter, prospective, non-randomized, open-label, clinical study to evaluate the safety and effectiveness of the LAP-BAND® AP System in a lower obese population (BMI ≥ 30 kg/m2 and < 40 kg/m2) with…
- Trial name
- NCT02356614
- Where
- 11 sites in United States
- Volunteers
- 325 people
- Sponsor
- Apollo Endosurgery, Inc.
Healthy
A Study of RAY1225 at Different Injection Sites in Participants With Different Body Sizes
The purpose of this study is to compare the amount of RAY1225 that gets into the blood stream and how long it takes the body to get rid of it, when injected under the skin of the upper arm and thigh compared to the abdomen.
- Trial name
- NCT06577428
- Testing
- RAY1225
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Schizophrenia, Schizoaffective Disorder
Study on the Safety of Risperidone on Obese or Overweight Patients With Schizophrenia
The purpose of this study is to evaluate the safety of risperidone treatment in patients who are overweight and/or obese.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00511628
- Testing
- Risperidone
- Volunteers
- 1,717 people
- Sponsor
- Janssen-Cilag, S.A.
Schizophrenia, Schizoaffective Disorder
Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)
This study is testing if under the tongue olanzapine for schizophrenia, related psychosis, schizoaffective disorder or bipolar disorder will have less weight gain than olanzapine that is swallowed, in patients who are already…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00303602
- Testing
- Sublingual orally disintegrating olanzapine (SODO), Oral olanzapine
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 149 people
- Sponsor
- Eli Lilly and Company
Cardiovascular Disease, Overweight
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27
The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to…
- Trial name
- PLATO-dose (NCT01509365)
- Testing
- clopidogrel
- Where
- Tunisia
- Volunteers
- 116 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Healthy Participants
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Enicepatide in Generally Healthy Adult Chinese Participants
This is a Phase I, randomized, double-blinded, placebo-controlled, study to assess the safety, tolerability, and pharmacokinetics (PK) of enicepatide in generally healthy adult Chinese participants with body mass index (BMI)…
- Trial name
- NCT07626515
- Testing
- Enicepatide
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Obesity, Overweight
A Safety and Efficacy Study of HPP404 on Weight Loss in Overweight or Obese Subjects
The purpose of this study is to compare the safety and effect of HPP404 versus placebo on body weight in overweight or obese subjects.
- Trial name
- NCT01540864
- Testing
- HPP404
- Where
- 10 sites in United States
- Volunteers
- 126 people
- Sponsor
- High Point Pharmaceuticals, LLC.
Normal Healthy Volunteer, Safety After Oral Intake
A Research Study to Evaluate BLX-7006 in Healthy Adults
This study will test an oral medicine called BLX-7006, which acts like the hormone Glucagon-like Peptide-1 (GLP-1) to help control blood sugar and body weight. Current GLP-1 medicines are given by injection.
- Trial name
- NCT07140055
- Testing
- BLX-7006
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics
Obesity, Overweight
A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
Phase 2 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of various aleniglipron (GSBR-1290) dose regimens compared with placebo in participants living with obesity or overweight with ≥ 1…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- ACCESS II (NCT06703021)
- Where
- 10 sites in United States
- Volunteers
- 85 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity
Technical Validation of Lunar iDXA (GE Healthcare) Visceral Fat Tool
The goal of this project is to compare visceral fat measurements derived from Lunar iDXA total body scans and from Computed Tomography (CT) scans of the abdominal region.
- Trial name
- NCT00987298
- Testing
- Visceral fat mass measurement
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Obesity
Study of Low Level Laser Therapy to Reduce Body Circumference in Obese Individuals
The purpose of this study is to determine whether low level laser light therapy is effective in reducing circumference of the waist, hips and upper abdomen in obese individuals.
- Trial name
- NCT01821352
- Testing
- Erchonia Obesity Laser
- Where
- 2 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Erchonia Corporation
Obesity, Overweight, or Chronic Weight Management
A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at…
- Trial name
- ACCESS (NCT06693843)
- Testing
- Aleniglipron
- Where
- 39 sites in United States
- Volunteers
- 230 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Weight Loss, NASH
Phase 1 Study to Evaluate the Safety and Tolerability of VK2735
This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of VK2735 in healthy adults and…
- Trial name
- NCT05203237
- Testing
- VK2735, VK2735 Drug
- Where
- Australia
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Viking Therapeutics, Inc.
Normal Healthy Adults
A Research Study to Evaluate BLX-0871 in Healthy Adults
This study will test an oral medicine called BLX-0871, which is being developed to improve metabolic health by activating AMP-activated protein kinase (AMPK), a key regulator of energy balance.
- Trial name
- NCT07140081
- Testing
- BLX-0871
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Biolexis Therapeutics